Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Towards a pan-serotype dengue antiviral

  1. Sarah Crunkhorn
    View author publications

    You can also search for this author in PubMed  Google Scholar

The development of antiviral agents for the treatment of dengue virus (DENV) — a mosquito-borne flavivirus that can cause haemorrhagic fever and death — faces significant challenges related to delivery, safety and the need for pan-serotype efficacy. Writing in Nature, Kaptein et al. describe a highly potent pan-serotype DENV inhibitor, capable of preventing and treating DENV infection in mouse models.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 20, 895 (2021)

doi: https://doi.org/10.1038/d41573-021-00178-5

References

  1. Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction. Nature https://doi.org/10.1038/s41586-021-03990-6 (2021)

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links